All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-12-13T14:52:47.000Z

What are the most promising CAR T therapies in development for multiple myeloma?

Dec 13, 2019
Share:

Bookmark this article

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Nina D. Shah, University of California, San Francisco, US, answers the question: What are the most promising CAR T therapies in development for multiple myeloma?

Dr Shah comments on some of the exciting abstracts due to be presented at the ASH meeting including; data from a longer follow-up of the LEGEND-2 trial in China, and the US equivalent trial, CARTITUDE, as well as an update from the bb21217 trial. Dr Shah also highlights an abstract on the use of a gamma secretase inhibitor, in combination with anti-BCMA CAR T, in order to increase BCMA expression on the myeloma-cell surface to improve efficacy.

Additionally, Dr Shah adds that there are more CAR T trials than ever before, with other strategies to improve efficacy including the targeting of multiple antigens. Lastly, Dr Shah notes that whilst it is not a CAR T product, some of the new bispecific T-cell engagers (BiTEs) are not given as a continuous infusion and therefore may represent another patient-friendly immunotherapy option.

What are the most promising CAR T therapies in development for multiple myeloma?

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox